Aranesp

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

darbepoetin alfa

Available from:

Amgen Europe B.V.

ATC code:

B03XA02

INN (International Name):

darbepoetin alfa

Therapeutic group:

Önnur antianemic undirbúningur

Therapeutic area:

Anemia; Cancer; Kidney Failure, Chronic

Therapeutic indications:

Meðferð við blóðleysi með einkennum í tengslum við langvarandi nýrnabilun (CRF) hjá fullorðnum og börnum. Meðferð einkennum blóðleysi í fullorðinn krabbamein sjúklinga með ekki-merg illkynja fá lyfjameðferð.

Product summary:

Revision: 45

Authorization status:

Leyfilegt

Authorization date:

2001-06-08

Patient Information leaflet

                                192
B. FYLGISEÐILL
193
FYLGISEÐILL: UPPLÝSINGAR FYRIR NOTANDA LYFSINS
ARANESP 10 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 15 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 20 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 30 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 40 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 50 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 60 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 80 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 100 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 130 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 150 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 300 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
ARANESP 500 MÍKRÓGRÖMM STUNGULYF, LAUSN Í ÁFYLLTRI SPRAUTU
darbepoetin alfa
LESIÐ ALLAN FYLGISEÐILINN VANDLEGA ÁÐUR EN BYRJAÐ ER AÐ NOTA
LYFIÐ. Í HONUM ERU MIKILVÆGAR
UPPLÝSINGAR.
-
Geymið fylgiseðilinn. Nauðsynlegt getur verið að lesa hann
síðar.
-
Leitið til læknisins, lyfjafræðings eða hjúkrunarfræðingsins
ef þörf er á frekari upplýsingum.
-
Þessu lyfi hefur verið ávísað til persónulegra nota. Ekki má
gefa það öðrum. Það getur valdið
þeim skaða, jafnvel þótt um sömu sjúkdómseinkenni sé að
ræða.
-
Látið lækninn, lyfjafræðing eða hjúkrunarfræðinginn vita um
allar aukaverkanir. Þetta gildir
einnig um aukaverkanir sem ekki er minnst á í þessum fylgiseðli
(sjá kafla 4).
Í FYLGISEÐLINUM ERU EFTIRFARANDI KAFLAR:
1.
Upplýsingar um Aranesp og við hverju það er notað
2.
Áður en byrjað er að nota Aranesp
3.
Hvernig nota á Aranesp
4.
Hugsanlegar aukaverkanir
5.
Hvernig geyma á Aranesp
6.
Pakkningar og aðrar upplýsingar
7.
Leiðbeiningar fyrir inndælingu Aranesp með áfylltu sprautunni
1.
UPPLÝSINGAR UM ARANESP OG VIÐ HVERJU ÞAÐ ER NOTAÐ
Læknirinn hefur ávísað Aranesp (lyf við blóðleysi) til að
meðhönd
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
2
1.
HEITI LYFS
Aranesp 10 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 15 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 20 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 30 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 40 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 50 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 60 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 80 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 100 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 130 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 150 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 300 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 500 míkrógrömm stungulyf, lausn í áfylltri sprautu.
Aranesp 10 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 15 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 20 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 30 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 40 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 50 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 60 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 80 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 100 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 130 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 150 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 300 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 500 míkrógrömm stungulyf, lausn í áfylltum penna.
Aranesp 25 míkrógrömm stungulyf, lausn í hettuglasi.
Aranesp 40 míkrógrömm stungulyf, lausn í hettuglasi.
Aranesp 60 míkrógrömm stungulyf, lausn í hettuglasi.
Aranesp 100 míkrógrömm stungulyf, lausn í hettuglasi.
Aranesp 200 míkrógrömm stungulyf, lausn í hettuglasi.
Aranesp 300 míkrógrömm stungulyf, lausn í hettugla
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 11-11-2022
Public Assessment Report Public Assessment Report Bulgarian 14-05-2019
Patient Information leaflet Patient Information leaflet Spanish 11-11-2022
Public Assessment Report Public Assessment Report Spanish 14-05-2019
Patient Information leaflet Patient Information leaflet Czech 11-11-2022
Public Assessment Report Public Assessment Report Czech 14-05-2019
Patient Information leaflet Patient Information leaflet Danish 11-11-2022
Public Assessment Report Public Assessment Report Danish 14-05-2019
Patient Information leaflet Patient Information leaflet German 11-11-2022
Public Assessment Report Public Assessment Report German 14-05-2019
Patient Information leaflet Patient Information leaflet Estonian 11-11-2022
Public Assessment Report Public Assessment Report Estonian 14-05-2019
Patient Information leaflet Patient Information leaflet Greek 11-11-2022
Public Assessment Report Public Assessment Report Greek 14-05-2019
Patient Information leaflet Patient Information leaflet English 11-11-2022
Public Assessment Report Public Assessment Report English 14-05-2019
Patient Information leaflet Patient Information leaflet French 11-11-2022
Public Assessment Report Public Assessment Report French 14-05-2019
Patient Information leaflet Patient Information leaflet Italian 11-11-2022
Public Assessment Report Public Assessment Report Italian 14-05-2019
Patient Information leaflet Patient Information leaflet Latvian 11-11-2022
Public Assessment Report Public Assessment Report Latvian 14-05-2019
Patient Information leaflet Patient Information leaflet Lithuanian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 11-11-2022
Public Assessment Report Public Assessment Report Lithuanian 14-05-2019
Patient Information leaflet Patient Information leaflet Hungarian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 11-11-2022
Public Assessment Report Public Assessment Report Hungarian 14-05-2019
Patient Information leaflet Patient Information leaflet Maltese 11-11-2022
Public Assessment Report Public Assessment Report Maltese 14-05-2019
Patient Information leaflet Patient Information leaflet Dutch 11-11-2022
Public Assessment Report Public Assessment Report Dutch 14-05-2019
Patient Information leaflet Patient Information leaflet Polish 11-11-2022
Public Assessment Report Public Assessment Report Polish 14-05-2019
Patient Information leaflet Patient Information leaflet Portuguese 11-11-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 11-11-2022
Public Assessment Report Public Assessment Report Portuguese 14-05-2019
Patient Information leaflet Patient Information leaflet Romanian 11-11-2022
Public Assessment Report Public Assessment Report Romanian 14-05-2019
Patient Information leaflet Patient Information leaflet Slovak 11-11-2022
Public Assessment Report Public Assessment Report Slovak 14-05-2019
Patient Information leaflet Patient Information leaflet Slovenian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 11-11-2022
Public Assessment Report Public Assessment Report Slovenian 14-05-2019
Patient Information leaflet Patient Information leaflet Finnish 11-11-2022
Public Assessment Report Public Assessment Report Finnish 14-05-2019
Patient Information leaflet Patient Information leaflet Swedish 11-11-2022
Public Assessment Report Public Assessment Report Swedish 14-05-2019
Patient Information leaflet Patient Information leaflet Norwegian 11-11-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 11-11-2022
Patient Information leaflet Patient Information leaflet Croatian 11-11-2022
Public Assessment Report Public Assessment Report Croatian 14-05-2019

Search alerts related to this product

View documents history